Malignant Mesothelioma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
The PDQ adult treatment editorial board reviewed and updated the summary on April 24, 2024.
This PDQ cancer information summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about the treatment of adult malignant mesothelioma. It is intended as a resource to inform and assist clinicians in the care of their patients and does not provide formal guidelines or recommendations for making health‑care decisions. The summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI).
This article summarises current evidence and key prognostic factors for malignant mesothelioma, informing clinical decision‑making for survivors and healthcare providers.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma